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Effective risk communication is challenging. Ensuring potential trial participants’ understand
‘risk’ information presented to them is a key aspect of the informed consent process within
clinical trials, yet minimal research has looked specifically at how to communicate probabili-
ties to support decisions about trial participation. This study reports a systematic review of
the literature focusing on presentation of probabilistic information or understanding of risk by
potential trial participants.
Methods
A search strategy for risk communication in clinical trials was designed and informed by
systematic reviews of risk communication in treatment and screening contexts and supple-
mented with trial participation terms. Extracted data included study characteristics and the
main interventions/findings of each study. Explanatory studies that investigated the meth-
ods for presenting probabilistic information within participant information leaflets for a clinical
trial were included, as were interventions that focused on optimising understanding of prob-
abilistic information within the context of a clinical trial.
Results
The search strategy identified a total of 4931 studies. Nineteen papers were selected for full
text screening, and seven studies included. All reported results from risk communication
studies that aimed to support potential trial participants’ decision making set within hypothet-
ical trials. Five of these were randomised comparisons of risk communication interventions,
and two were prospectively designed, non-randomised studies. Study interventions focused
on probability presentation, risk framing and risk interpretation with a wide variety of inter-
ventions being evaluated and considerable heterogeneity in terms of outcomes assessed.
Studies show conflicting findings when it comes to how best to present information, although
numerical, particularly frequency formats and some visual aids appear to have promise.
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Conclusions
The evidence base surrounding risk communication in clinical trials indicates that there is as
yet no clear optimal method for improving participant understanding, or clear consensus on
how it affects their willingness to participate. Further research into risk communication within
trials is needed to help illuminate the mechanisms underlying risk perception and under-
standing and provide appropriate ways to present and communicate risk in a trial context so
as to further promote informed choices about participation. A key focus for future research
should be to investigate the potential for learning in the evidence on risk communication
from treatment and screening decisions when applied to decisions about trial participation.
Introduction
Clinical trials are now widely accepted as the gold standard of evidence-based medicine for
determining treatment effects [1]. The importance of recruiting adequately informed individu-
als to participate in clinical trials is paramount. However many studies have demonstrated that
participants approached to take part and those consented to participate in trials have a limited
understanding of key aspects of the trial [2]. One of the key areas to consider when presenting
information to potential participants is the information on potential risks and benefits. The
ethical principles for medical research involving human subjects, enshrined within the Decla-
ration of Helsinki, state that ‘each potential subject must be adequately informed of the antici-
pated benefits and potential risks of the study’ [3]. This is echoed by guidelines for good
clinical practice, which state that all the information provided to participants should include
explanations of the ‘reasonably foreseeable risks or inconveniences’, expected benefits, and
where there are no clinical benefits to the participants, they must be made aware of this’ [4].
However, mechanisms to operationalise the provision of such information are not provided in
the guidance.
Risk communication can be defined as communication with individuals that addresses
knowledge, perceptions, attitudes and behaviour related to risk, and risk itself can be defined
as the probability that a hazard will give rise to harm [5, 6]. A correct understanding of risk
therefore depends upon an accurate understanding of probabilities, a feat that is determined
by several influencing factors, such as individual numeracy levels and cognitive abilities, but
not least by the methods used to present probabalistic information [7]. There is a substantial
amount of literature that focuses on risk communication with regard to public health mes-
sages, health behaviour, and treatment and screening decisions for patients [8–11]. Speigelhal-
ter et al have shown that probabilities are ‘notoriously difficult to communicate effectively’ to
lay audiences in various contexts, including health [12]. Yet minimal research has looked spe-
cifically at how to communicate probabilities within information provided to support deci-
sions about trial participation (or not). In a trial context uncertainties relating to interventions
will usually be greater purely by the nature of the trial endeavour—to generate evidence about
benefit and harm.
Understanding, or more often mis-understanding, of risk information related to trials has
been shown to influence decisions about participation in a range of trials, with those prepared
to accept risk more likely to participate [13, 14]. Decisions about trial participation are inher-
ently different from decisions about treatment. For example, one of the main influences on
clinical trial participation is conditional altruism [13]. Conditional altruism is the concept that
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participation in the trial will benefit society but there must be a benefit (which is influenced by
perception of risk) for self. Conditional altruism does not exist for decisions about treatment
and as such it is important to understand how potential trial participants understand risk in a
trial participation context. Additionally, trade-offs between risk and benefit in a trial involve
layers of complexity in addition to those for treatment such as: loss of control over which treat-
ment they receive; and potentially greater uncertainties, as often participants have to consider
the risks and benefits of a minimum of two competing treatments. Existing studies in the
domain of informed consent for clinical trials have repeatedly highlighted significant discrep-
ancies between actual risk and participant interpretation of risk to themselves, or their child,
in taking part in a trial [15, 16]. Participants frequently underestimate risks, leading them to
believe that there would be little to no risk involved in trial participation. This pronounced
lack of understanding strongly suggests the need for better communication about trial aims
and design, particularly when it comes to the inherent risks, however small, that are almost
always present in taking part in a clinical trial [15]. The intrinsic nature of trials means there is
much unknown information and communicating probabilistic information in this context is
more challenging as the layers of risk are greater, for example the risk of undertaking a trial as
opposed to treatment, the outcome risks, and the risk of randomisation to a drug, procedure
or placebo [17].
Preliminary findings from our group have shown that stakeholders have varied preferences
about how probabilistic information relevant to trial participation (e.g. estimates of the likeli-
hood of benefit and/or harm associated with trial interventions) is communicated [18]. In
addition, a pilot study exploring decision support for trial participation decisions highlighted
that patients’ preferences for risk information differed in a trial context compared to a treat-
ment context [19]. Existing research on methods to present probabilistic information to
improve patient understanding and decision making about treatment and screening decisions
could provide valuable insights for enabling effective risk communication in the context of
informed consent for trials [20]. Yet, surprisingly, the methods shown to be effective to
improve understanding of probabilistic information are not routinely employed in participant
information leaflets for trial participation [17].
A small number of studies have evaluated methods for presenting ‘risk’ in patient informa-
tion leaflets for clinical trials. However, these studies have not been analysed together to allow
judgements about optimal methods of presentation. This warrants further investigation both
at the level of understanding and on the decision to participate (or not) in the trial. To address
this, this study aimed to systematically review the literature focusing on presentation of proba-
bilistic information within the informed consent process for trials. We focused our search on
comparative effectiveness studies that tested interventions which varied the presentation of
probabilistic information and the effects on potential trial participants’ understanding and/or
the decision to participate.
Methods
Inclusion criteria
Evaluative studies using qualitative methods that investigated the methods for presenting
probabilistic information to potential trial participants during the informed consent process
for a trial were considered eligible. Specific study designs could include randomised controlled
trials, case series, and prospective cohorts. Interventions that focused on optimising under-
standing (or another plausible outcome linked to decision making for trial participation) of
probabilistic information within the context of a clinical trial were included. We chose to
include studies of both real and hypothetical decisions about trial participation.
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Exclusion criteria
Papers or articles that present findings on risk communication in a treatment or screening
context or consider the decision to participate in research studies that are not RCTs were
excluded. Studies investigating participants’ perceptions of receiving risk communication as
part of the RCT decision process (which may include studies using methods such as interviews,
focus groups and other methods) were not included.
Search methods for identification of studies
A search strategy for risk communication in clinical trials was designed in collaboration with a
Senior Information Specialist (skilled in developing and running search strategies to identify
relevant scientific literature) and informed by systematic reviews of risk communication in
treatment and screening contexts and supplemented with trial participation terms. The search
strategy is available on request. Four data bases were searched. Embase was searched from
1980 to 2019. Ovid MEDLINE(R) Epub Ahead of print, In-Process & other Non-Indexed Cita-
tions, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) was searched from 1946 to May 10th
2019. PsycINFO was searched from 1987 to May week 2 2019. Finally, CINAHL was searched
from 1998 to 2019. No restrictions on language were imposed.
Screening and selection of studies
One author (MC) screened all articles identified within the database searches. Duplicate
screening was carried out by one other author (KG) on a random sample (10%) of the search
output. Papers were assessed at title and abstract level according to the eligibility criteria, and
differences of opinion were resolved by discussion between MC and KG. Nineteen full text
papers were identified for further investigation, and of these seven studies were deemed eligi-
ble for inclusion and progressed to data extraction procedures.
Data collection and analysis
The seven studies were summarised by study characteristics (see details below) and presented
in tabular form. Due to the heterogeneous nature of the interventions and/or outcomes
reported a meta-analysis was not appropriate. This review is therefore presented in a descrip-
tive narrative form with studies grouped first by design of the embedded study (RCT, non-ran-
domised) and then by content of intervention i.e., probability presentation, risk framing, risk
intervention. This structured framework to present narrative findings has been recently pro-
posed by Rowlands et al 2018 [21].
Data extraction and management
Data were extracted independently by two reviewers (MC & KG). The following summary fea-
tures of the host trial (i.e. the trial the potential participants were being asked to consider par-
ticipation in) for each study were summarised in table form: study design; study aim; author
details; year and journal of publication; population demographics; sample size; phase of trial;
intervention(s). Specific details on the intervention(s) being evaluated (i.e., risk communica-
tion tools), embedded study results and associated outcomes were extracted. These included:
comparative methods of disseminating probabilistic information to potential trial participants
using different communication tools/aids; mode of intervention delivery (i.e., paper, com-
puter, verbal); study outcomes to be extracted; cognitive outcomes (i.e., potential trial partici-
pant comprehension of probabilistic information and subsequent risk perception); affective
outcomes (i.e., participant preferences and/or satisfaction with communication method, and
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level of decisional conflict and concern); and behavioural outcomes linked to trial participation
(i.e., willingness to participate in clinical trial).
Results
Study selection and summary characteristics
The search strategy identified a total of 4931 studies. Full text papers for 19 potentially eligible
studies were sourced, and following full text screening a further 12 studies were excluded from
the review (Fig 1). The included seven studies all reported results from studies set within hypo-
thetical randomised controlled trials [22–28]. To provide an example of how this embedded
evaluation is operationalised, the studies asked participants to imagine they were being
recruited into a clinical trial, provided brief information about the hypothetical trial (such as
clinical population, intervention, comparator, outcomes, etc), then provided various formats
of risk communication (such as verbal or numerical descriptors) followed by assessment of rel-
evant outcomes.
Fig 1. The PRIMSA diagram details our search and selection process applied during the literature review.
https://doi.org/10.1371/journal.pone.0242239.g001
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The seven included studies had various designs: five were randomised comparisons of risk
communication interventions considering participation in hypothetical RCTs; and two were
prospective, non-randomised studies, one being a comparative cohort study (three groups)
and the other a single cohort. The included studies spanned a range of clinical settings. Three
of the included studies were trials in neurological settings, and the other four were within der-
matology, cardiology, oncology and surgery. Only one study was set within a trial considering
a non-drug intervention, where the other six were identified as trials testing drug-based inter-
ventions. All of the included studies had at least two arms as part of their hypothetical trial
design. Six of the seven studies reported trials where an individual was considering consenting
for themselves and one study included only parents who were considering participation for
their child. Most studies were single centre, however two of the studies did not specify the
number of centres involved. The number of participants in the embedded studies ranged from
50 to 4885 with a median of 240. (Table 1).
The final seven studies were grouped according to the study design (i.e., RCT or prospective
cohort) and the topic of the described intervention: ‘probability presentation’ (22, 23), ‘risk
framing’ (24, 25, 26, 27), and ‘risk interpretation’ (28). The studies are presented alphabetically
based on these similar characteristics under their category headings (Table 2). Further infor-
mation on each study detailing intervention content, mode, and outcome are presented in
Table 3.
RCTs of interventions to explore risk communication in RCTs
Probability presentation interventions. One study was identified that used a randomised
design to investigate different probability presentations in the context of risk communication
Table 1. Summary characteristics of hypothetical host trials.
Trial characteristic Hypothetical RCTs (n = 7)
Clinical setting
Dermatology 1
Neurology (pain x 2, ALS) 3
Cardiology 1
Oncology 1






Two groups 2 (Berry, Kim)









Median no of participants (range) 240 (50–4885)
https://doi.org/10.1371/journal.pone.0242239.t001
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in clinical trials. Berry & Hochhauser (2006), compared European Union (EU) verbal descrip-
tors only versus verbal descriptors and their associated numerical values (e.g., Common (EU
equivalent = 1–10%)) [22]. Participants were asked to imagine they had been approached to
take part in a clinical trial and given a booklet detailing the possible side effects of a new drug
(versus nothing) for a skin condition and were asked to complete a questionnaire (N = 96, 48
in each arm). When asked to rate on a scale from 1 to 6 (p = 0.03), those who received only ver-
bal descriptors were significantly less satisfied with the information than those who also had
the numerical values. Participants in the verbal descriptors only group also perceived the risk
to health to be higher (p<0.0001) and the benefit to be lower (p = 0.03), and were significantly
less likely to participate in the trial (p = 0.01). When asked to make probability estimates for
experiencing side effects, the verbal only group estimated these approximately three times
higher than the combined group. When asked to consider the main reason for participating in
the trial, participants in both groups reported long term relief/possible cure and the main rea-
son for not participating was fear of side effects. There were no significant differences between
the reasons listed by the two groups.
Risk framing interventions. Four of the included studies employed randomised designs
to explore risk framing in communication within clinical trials. Kim et al (2015) recruited 584
participants to investigate the language framing of benefit statements within a hypothetical
trial for amyotrophic lateral sclerosis. An online survey administered one of two statements
within a consent form to participants; either ‘there is some but very small chance that you
might benefit’ (control group n = 290), or ‘it is not guaranteed you will benefit’ (intervention
group n = 294) [24]. The intervention group had a slightly greater, but not significant, willing-
ness to participate in the trial as scored on a 10 point scale (p = 0.11). However, the average
estimate of the likelihood of their condition improving was significantly higher in the interven-
tion group than in the control group (p<0.0001).
Schwartz & Hasnain (2002) explored the effects of gain and loss framing on risk perception
and attitude by randomising 284 participants to one of three groups receiving a consent form
about a trial for a new cholesterol lowering drug [25]. One group were given information
where benefits were framed in terms of gains (e.g., ‘Out of 100 people whose lives would likely
be cut short by heart disease and begin taking this drug, we expect that 95 will show substantial
improvements in their chance of survival and 5 will show no improvement in survival’,
n = 98), the ‘loss’ group received benefit information framed as losses (e.g.,. ‘Out of 100 people
whose lives would likely be cut short by heart disease and begin taking this drug, we expect
that 5 people will go on to die from heart disease, and 95 people will reduce their chance of
death’, n = 93), and the third group were given information where both framings were pre-
sented (e.g.,. ‘Out of 100 people whose lives would likely be cut short by heart disease and
begin taking this drug, we expect that 5 people will show no improvement and will go on to
die from heart disease, and 95 people will substantially improve their chance of survival and
reduce their chance of death’, n- = 93). The majority of participants (59%) chose to take part in
Table 2. Catalogue of included studies by study design and real or hypothetical RCT setting.
Category Risk communication study design Real RCTs Hypothetical RCTs





B Prospectively designed, non-randomised studies of interventions to explore risk communication within RCTs N/A Cheung
Sutherland
https://doi.org/10.1371/journal.pone.0242239.t002
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Table 3. Types of intervention(s) reported in included studies.
Author/Date Content Mode Outcome





Intervention communicates risk for the ‘experimental’ drug
only
Two experimental conditions: probability of side effects
described using verbal descriptors, or verbal descriptors with
associated numerical ranges. i.e.
• Common (EU equivalent = 1–10%)
• Uncommon (EU equivalent 0.1–1%)
• Rare (EU equivalent = 0.01%-0.1%)
Written four-page
questionnaire booklet
• Satisfaction with the information; perceived risk to
health from taking the drug; perceived effectiveness of
the drug; how beneficial for their health it would be if
they took part in the trial; and how likely it was that they
would participate. (assessed using a 6-point unipolar
Likert rating scale)
• Estimation of the probability of their experiencing each
side effect as a percentage, between 0% and 100%.
• Main reasons for taking part or not
Risk framing interventions
Kim et al 2015 Intervention communicates risk for the ‘experimental’ drug
only
One of two statements: in ‘no guarantee’ group, the
likelihood was described as ‘It is not guaranteed you will
benefit’; in ‘control’ group likelihood described as ‘There is
some but very small chance that you might benefit’
Online survey • Willingness to participate in trial on a 10-point scale,
from ‘would not consider at all’ = 0, to ‘definitely would
consider’ = 10.
• Likelihood that ALS would improve from being in this
study, from 0% to 100%.
Schwartz &
Hasnain 2002
Intervention communicates risk for the ‘experimental’ drug
only
Information in each group’s consent form was identical
except for the second paragraph describing the probable risks
and benefits of the new drug.
In the ‘gain’ group, benefits were framed in terms of gains,
benefits were framed as losses in the ‘loss’ group, and in the
‘both’ group, both framings were presented i.e.:
‘Anyone taking this drug has a small risk of a severe allergy
that could result in death. Out of 100 people whose lives
would likely be cut short by heart disease and begin taking
the drug, we expect that 5 people will show no improvement
and will go on to die from heart disease (loss), and 95 people
will substantially improve their chance of survival and reduce
their chance of death (gain)’
Paper based • Riskiness of participation in the clinical and riskiness of
non-participation in the clinical trial on a category rating
scale from 1 (not at all risky) to 10 (extremely risky)
• Willingness to participate in trial (yes or no)
Tait et al 2010 Intervention communicates risk for both interventions
(drug)
Three different risk/benefit message formats (text, tables or
pictographs), and the presence or absence of a risk severity
graphic.
Risks (itching and slowed breathing) and benefit (pain relief)
were communicated in one of the three different formats.
Comparing risks and benefits between drugs A and B:
absolute risk of occurrence for drug A was presented;
information for drug B was presented as incremental risk
increase or decrease.
Online survey • Verbatim understanding (the ability to correctly report
the actual risk and benefit frequencies of drugs A and B)
• Gist understanding (the ability to identify the essential
meaning about the observed differences between the
risks and benefits of drugs A and B)
• Perceptions of the risks and benefits of drugs A and B
e.g. ‘how worried would you be about your child
experiencing pain after surgery?’. Also perceptions of
frequency and severity of side effects, scored using 1–11
interval scales from e.g. ‘not at all likely/worried’ to
‘extremely likely/worried’ etc.
• Perceptions of the risk/benefit communication format
Treschan et al
2003
Intervention communicates risk for both the control and the
treatment group
Three versions of study protocol: ‘control’ involved little if
any risk or pain; ‘pain’ required additional procedures that
were described as provoking considerable pain and
discomfort; and ‘risk’ involved additional procedures that




• Willingness to participate (yes or no)
• Understanding of risks involved in participation i.e.
asked to mark the statement they found most applicable:
A. ‘Participation in this study is not associated with
additional risks, discomfort or pain’, B. ‘Participation in
this study is associated with additional risks, but does not
cause any discomfort or pain’, and C. ‘Participation in
this study is not associated with additional risks, but
might cause discomfort or pain’.
• Factors that influenced willingness to consent
Prospectively designed, non-randomised studies of interventions to explore risk communication within RCTs
Probability presentation interventions
(Continued)
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the trial when outcomes were framed as losses, while only 35% of the ‘gain’ group chose to par-
ticipate. When both framings were presented, 62% of participants chose to participate, making
a similar choice to the ‘loss’ group. When it came to perceiving riskiness of participation, the
‘gain’ group were more likely to rate this as riskier than non-participation (66%) compared to
the ‘loss’ group (55%). For the ‘both’ group, the results were again similar to the loss condition,
with 52% reporting trial participation as riskier than not. Respondents in the gain condition
rated participation as significantly riskier (on a 10 point scale) than those in the loss condition
(p<0.05), and respondents in the loss condition rated non-participation as significantly riskier
than those in the gain condition (p<0.05). There was a significant association between domain
(gains vs loss) and relative riskiness of participation vs non-participation (p<0.05).
In the study by Tait et al [26] 4685 parents were asked to consider their child was being ran-
domised into a trial testing two drugs for post-operative pain, one a standard treatment and
the other proven in adults but not in children. The risks and benefits of the two drugs were
presented in absolute terms with comparisons presented as incremental changes. Four scenar-
ios that provided different risk/benefit trade-offs were developed and considered: one benefit
and 2 risks (a minor and a major), which were varied for Drug B across each scenario but
remained static for Drug A. There was one scenario with no trade off, where there was an
increase in benefit as well as risk reduction (n = 1171), whereas the other three included a loss
of benefit but gains in risk reduction (n = 1184, n = 1196, n = 1134). Overall the study showed
that parents who received the ‘no trade off’ (i.e., improvements across benefit and risk) sce-
nario had both improved gist (defined as ‘ability to identify the essential meaning about the
observed differences’ and measured using 4 items where�3 correct answers were required,
p<0.01) and verbatim understanding (defined as understanding or knowledge to ‘correctly
report the actual risk and benefit frequencies’ and measured using 7 items where�5 correct
answers were required, p<0.01). The no trade off scenario also enabled parents to correctly
perceive the potential benefits as greater, risks as lower, (p<0.01) and to be more likely to
agree to their child participating in the trial (measured using an 11 point scale) compared to
Table 3. (Continued)
Author/Date Content Mode Outcome
Cheung et al
2010
Intervention communicates risk for the new medication only
Three formats of risk presentation: frequency, percentage
and verbal descriptors. The verbal description followed the
EU guideline on drug labelling; risk levels of�0.01%,
>0.01% to 0.1%, >0.1% to 1%, >1% to 10%, and >10% were
described as ‘very rare’, ‘rare’, ‘uncommon’, ‘common’ and
‘very common’ respectively.
Card 1 showing information about side effects of a new
medication for pain relief in one of 6 ways of risk
presentation.
Card 2 with the same risk information presented in all three
formats (in the same sequence in severity)
Paper based • Willingness to participate in trial after card 1
presentation, and then willingness to participate in trial
after card 2 presentation;
• A change in decision would indicate a potential problem
in the initial format.
• Preference for risk communication
• Understanding of EU descriptors: which of the five
(from ‘very rare’ to ‘very common’) best describe the
frequency of 1 out of 40, 1 out of 4,000, 1 out of 5, 1 out




Intervention communicates risk for the ‘experimental’ drug
only
Patients asked to underline statements in the consent form
that were pertinent to making a decision about participating
in the study.
Three statements about the likelihood of certain events
occurring were given; ‘itchy, red skin rashes are unlikely to
occur’, ‘a particular type of cancer responds to radiation
treatment in 10% of cases’, and ‘nausea and vomiting occurs
in 45% of patients’
Paper based • Willingness to participate in trial
• Understanding of three statements describing probability
of an event occurring.
• Preferences for the way potential benefits and risks or
side effects of therapy are described
• Preference for verbal and/or numerical descriptors of
probability
https://doi.org/10.1371/journal.pone.0242239.t003
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the other three groups (p<0.01). Taken together these results suggested the no trade off sce-
nario offering multiple gains resulted in a higher level of scrutiny compared to when only
reductions in risk were presented.
Treschan et al (2003) randomised 148 participants to one of three versions of a study proto-
col to examine how understanding of risk and discomfort associated with a clinical trial influ-
ences patients’ decision to participate [27]. The proposed trial was comparing peri-operative
oxygen (30% vs 80%) to reduce the risk of surgical site infections. The control group received a
version of the protocol that stated there would be little if any risk or pain involved in partici-
pating (n = 47), the ‘pain’ group were told that there would be additional procedures that
would cause considerable pain and discomfort (e.g., dressing of wounds, cannulation, blood
samples, n = 51)), and for the ‘risk’ group procedures were described as having a high risk of
injury (e.g.,. extra oxygen is dangerous, risks of cannulation, risk of blood samples, etc,
n = 50). Participants in the control group were more willing to participate in the trial (64%),
with significantly fewer consenting in the risky (26%) and painful (35%) groups (p<0.001).
There were no significant differences in understanding of the level of risk or pain for the three
groups (p = 0.884). Those who correctly understood the risk or pain described in the protocols
were twice as likely to consent to participation in the trial (49% vs 24%, p = 0.003).
Prospectively designed, non-randomised studies of interventions to explore
risk communication within RCTs
Probability presentation interventions. Of the two non-randomised papers that met the
inclusion criteria, Cheung et al (2010) is the only study that investigated probability presenta-
tion within risk communication for clinical trials [23]. This study implemented a cognitive
experiment (N = 240) and preference survey about risk within a hypothetical trial for pain
medication for arthritis. The intervention used a factorial design to study the impact of three
formats (frequency (n = 82), percentage (n = 80) and verbal descriptors (n = 78)) and two
sequences on willingness to participate and likelihood to change one’s willingness after given
additional information. Participants were presented with information in one of the six combi-
nations. Participants were given a card that showed information about side effects of a new
medication for pain relief in one of six ways of risk presentation, and then were asked whether
they would be willing to take part in the trial. They were then presented with a second card,
with the same risk information presented in all three formats being studied. A change in deci-
sion would indicate a potential problem in the initial format given to participants. There was
no difference in willingness to participate in the trial across all presentations (p = 0.886), and
there was also no difference in the likelihood of a participant changing their mind after being
given the information in additional formats (p = 0.529). After reading card 2, the proportion
of participants in each group showing a willingness to participate increased significantly
(p<0.05). With regardto presentation preferences, 43% of participants preferred the frequency
format, 32% preferred percentages, and 25% preferred the verbal descriptors.
Risk interpretation interventions. The remaining non-randomised study (Sutherland
et al, 1990) explored risk interpretation within a consent form for a hypothetical drug trial for
cancer [28]. All participants (N = 50) were given a consent form and asked to underline state-
ments that were important to them in terms of making a decision about participating in the
trial. They were also asked to indicate if their chosen statements were positive or negative. A
questionnaire including preferences for probability descriptors (verbal or numerical) was also
administered. Of those who refused to take part in the hypothetical trial, 70% noted only the
potential for risk, 10% only for benefit, and the remaining 20% noted both risk and benefit
information as important for their decision. Just 33% of those who ‘consented’ identified only
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risks, 27% noted only benefits, and 30% noted both risk and benefit. The remaining 10% iden-
tified neither as important to their decision. One third of participants were unable to identify
the correct interpretation of the ‘unlikely’ verbal descriptor, and 54% gave an incorrect inter-
pretation of ‘10% response rate’ meaning. When it came to preferences for benefit descriptors,
16% of patients preferred words, 34% numbers, 48% both and 2% other. For risk communica-
tion preference the results were very similar; 16% verbal, 28% numerical, 48% both and 2%
other.
Discussion
The study is one of the first to systematically review the published evidence on methods for
communicating risk to potential trial participants during the informed consent process. It has
examined and summarised the existing evidence about how risk information is perceived by
potential participants and highlights how these factors may influence decisions to participate
in a clinical trial context. Only seven studies were identified that have investigated aspects of
communicating risk information in a clinical trial setting. Whilst the majority of studies were
randomised comparisons, we also identified 2 non-randomised evaluations. Given the hetero-
geneity of the interventions investigated in the included studies and the variability in outcomes
reported, a meta-analysis of these studies was not possible. This work therefore highlights the
need for the rigorous development and evaluation of interventions to improve the presenta-
tion and communication of risk information for potential trial participants.
One of the studies investigated probabilistic presentation methods and demonstrated that
numerical formats appear to be better at communicating risk to potential trial participants,
when compared to text [22]. Participants receiving verbal descriptors alone were less likely to
consent to take part in a trial and were less satisfied with the information, perceiving risks of
side effects to be much higher than participants receiving both numerical and verbal descrip-
tors. Similar findings can be seen in a review on communicating with patients about evidence
(for treatment decisions), which illustrated that patients have a better understanding of risk if
probabilistic information is presented numerically rather than verbally [29]. It is worth consid-
ering that studies in a treatment setting have shown that using visual aids such as pictographs
or bar charts to present event rates may aid accurate understanding of probabilities, and they
can help reduce several biases including framing effects [30]. There are many variants of visual
aids however, and how these are utilised and understood by potential trial participants war-
rants more investigation using the best practice examples from treatment decision making as a
starter.
The second study (Cheung et al, 2010) looking at probabilistic presentation found no differ-
ence in willingness to participate between frequency, percentage and verbal conditions; how-
ever, it did find a strong preference for numerical presentations over verbal descriptors,
particularly for frequency formats [23]. Research by Price et al (2007) found that frequency
statements are generally better understood by participants compared to ratios or percentages
[31]. An important finding from this study highlighted major errors in correctly matching EU
descriptors of risk to associated frequencies, findings echoed by the other study which looked
at risk interpretation showing a large proportion of participants were unable to correctly inter-
pret verbal descriptors or percentage formats [28]. A number of studies have demonstrated
that many lay persons are unable to understand basic aspects of probabilities that are essential
to risk understanding, nor to comprehend the concept of risk in general [32, 33]. This poses a
challenge to effective risk communication and demonstrates a need for improved methods for
better informed consent within the context of clinical trials.
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The Sutherland et al (1990) study found that the majority of non-consenters to the trial
noted only the potential for risk in the provided information, whereas the information was
interpreted very differently by consenters where a minority saw only risks, and many perceived
benefits instead [28]. A qualitative study into patient decisions about taking part in an epilepsy
treatment trial noted that participant decision making was most commonly influenced by
their perception of harm and benefit [34]. Those who agreed to take part usually saw the risks
involved as acceptable, in this case because of the ‘tried and tested’ nature of treatments. How-
ever, the non-consenters viewed participation as ‘an unknown quantity’ and defined the risks
of being randomised to an unsuitable drug as being too high or not in their best interest [34].
When it came to studies looking at risk framing, the results were mixed. The study by Kim
et al found no significant difference in willingness to participate in the trial, although partici-
pants in the intervention group (no guarantee for benefit statement) were much more likely to
believe that their condition would improve [24]. When benefits were framed as losses partici-
pants were more likely to take part in the trial, and when benefits were presented as both losses
and gains, participants seemed to respond similarly to the loss group, suggesting that loss
framing had more impact on decision making than gain, where perceived risk was higher [25].
However, many of the statements used in this study were vague and uninformative, putting
into question what understanding participants had in relation to these statements in addition
to willingness to participate. Conversely, Treschan et al found that when outcomes were
framed as gains the majority of participants were less likely to participate [27]. Earlier research
by Tversky & Kahneman (1981) on framing and the psychology of choice demonstrated that
framing outcomes in terms of gains does indeed generate risk-averse choices, which could
translate to, for example, a decreased willingness to participate in a clinical trial [35]. A more
recent study highlighted the introduction of potential bias in decision making about trial par-
ticipation when the effects of language framing are not addressed [36]. This study explored
whether presenting health care decisions as ‘opportunity’ rather than ‘choice’ biased individu-
als’ preferences in the context of trial participation for cancer treatment. They found that a
‘choice’ frame, where all treatment options are explicit, is less likely to bias preferences [36]. It
is therefore of paramount importance that information given to participants include neutral
statements, or at a minimum balanced statement about participation or not, so as not to
unduly manipulate or ‘nudge’ decisions in ways that are not consistent with the individual’s
values and preferences [18].
Five out of the seven studies included in this review only communicated risk information
about the ‘experimental’ treatment [22–25, 28]. Two studies communicated risk information
about both the intervention and its comparator or indeed both active interventions [26, 27].
Given that decision making about clinical trials is complex and requires trade-offs between
both (or all) options and therefore presenting risk (and benefit) information on these options
would be important to support fully informed choices. This should be acknowledged and
explored in future studies.
Complex language and details included in participant information leaflets (PILs) and con-
sent forms for trials can be difficult for some people to comprehend properly and may engen-
der more confusion than understanding of trial processes, including risks [37]. An analysis of
PILs used in clinical trials by Gillies et al (2011) found that: explaining trial processes; present-
ing probabilities; and expressing values, were consistently poor across all PILs when assessed
using an informed consent evaluation instrument [17]. These information leaflets clearly need
to be improved to encourage higher quality decision making when it comes to trial participa-
tion. It is also clear that potential trial participants continue to have significant deficits in their
recall and understanding of trial related information, and that such information is often not
presented in a comprehensive way that optimises participant understanding [38, 39]. The
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recent study by Gillies et al (2014) explored whether patient information leaflets (PILs) were
able to effectively support decision making about trial participation [17]. They found that
information that demonstrated support for good quality decision making in other contexts
was lacking in PILs for UK clinical trials. In particular, the section on ‘presenting probabilities’
was almost always absent, despite its proven importance for supporting good quality decision
making [17].
Whilst not a focus of this review it is important to point out that none of the included stud-
ies reported including patients or the public as partners in the research to identify what the
content and/or presentation of the information should be for the studies. Also, no input was
sought with regard to whether the outcomes being evaluated were appropriate and meaningful
for patients faced with decisions about trial participation.
Lessons from effective risk communication in a treatment and/or screening context can
provide examples of best practice that could be used for those developing PILs for patients
considering clinical trial participation. A systematic review on risk communication published
since has shown that visual aids, such as icon arrays and bar graphs, improved both under-
standing and satisfaction [40]. Interestingly, this review showed that presenting absolute risk
reduction was better at maximising accuracy and less likely to influence decisions. The presen-
tation of information on numbers needed to treat reduced understanding. This review also
concluded that due to the quality and heterogeneity of included studies, it is not possible to
determine a ‘best’ method for conveying probabilistic information [40]. However, whilst there
might be a paucity of high quality evidence to support an unequivocal ‘best’ method there have
been recommendations for guiding principles developed by several groups. The first, devel-
oped using an international consensus process involving researchers and patients, provided
key considerations for presenting probabilities of outcomes [41]. These include:
• Use event rates to specify the population and time period
• Compare outcome probabilities using the same denominator, time period, and scale;
• Describe uncertainty around probabilities;
• Use visual diagrams;
• Use multiple methods to view probabilities (words, numbers, diagrams);
• Allow the patient to select a way of viewing the probabilities (words, numbers, diagrams);
• Allow patient to view probabilities based on their own situation (e.g. age);
• Place probabilities in context of other events;
• Use both positive and negative frames (e.g. showing both survival and death rates).
An expert consensus group further developed these IPDAS items to develop a set of guiding
principles and key messages which cover eleven components of risk communication and con-
sider what information to present and how it should be presented within tools such as patient
decision aids [42]. The guiding principles range from how best to present the chance an event
will occur, to use of interactive web-based platforms for delivery, and narrative methods for
communication [42]. A recent study published ‘good practice statements’ for the development
of evidence-based information communicating the effects of healthcare interventions [43].
Many of these statements would be relevant for developing information related to risk com-
munication to support decision about trial participation. For example: using numerical for-
mats that are easy to understand; present both numbers and words; and report absolute effects
[43]. In summary, whilst there may be a paucity of high quality evidence to underpin decisions
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about effective risk communication in clinical trial contexts, many of the good practice recom-
mendations developed through empirical research provide sensible frameworks to promote
informed choices, enable good quality decision making, and are unlikely to cause significant
harm. As such, these guiding principles could also serve as a foundation on which to develop
(and test) effective methods of risk communication within the context of clinical trials.
Strengths and limitations
The low number of studies included for review means it is difficult to confidently make far
reaching recommendations based on the findings, and the heterogenous nature of the studies
mean a meta-analysis was not feasible. The studies in our review included decisions about trial
participation that were hypothetical which may limit the extent to which these findings are
applicable to a real world setting. Understanding and assessing risk and risk communication is
pertinent to the trial phase, as the magnitude of risk is much greater in earlier phases of clinical
trials; however, only one of the studies stated the trial phase being investigated. This review is,
however, the first to systematically investigate risk communication within a clinical trial con-
text. With ever increasing numbers of trials, the importance of informed consent, and yet no
consistent, evidence-based format for presenting probabilistic information in a clinical trial
setting, this study supports the argument for effective future research within this area.
Conclusions
The evidence base surrounding risk communication in clinical trials indicates that there is as
yet no clear optimal method for improving participant understanding, nor a clear consensus
on how understanding affects willingness to participate, indicting a necessity for robust, high
quality research in this area. Further research into risk communication during the informed
consent process for trials, based on examples of best practice in other settings such as treat-
ment and screening decision making, is needed to help illuminate the mechanisms underlying
risk perception and understanding and provide appropriate ways to present and communicate
risk in a trial context so as to further promote informed choices about participation.
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